Clinical Trials Browser

Phase 1/2 × OTHER × Turcot syndrome × Clear all

NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT05426005 2026-05-22

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Turcot syndrome, Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Turcot syndrome, Rectal Neoplasms

NCT02992964 2024-04-02

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Phase 1/2 Terminated

Turcot syndrome

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms